We recently published a list of 9 Stocks Jim Cramer Talked About. In this article, we are going to take a look at where ...

In the closing of the recent trading day, CRISPR Therapeutics AG (CRSP) stood at $41.21, denoting a -1.44% change from the preceding trading day.

PFG Investments LLC lifted its stake in CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 9.9% in the 4th quarter, ...

Cathie Wood-led Ark Invest made significant trades involving CRSP, TXG, RBLX, ACHR, NU, ADYEY, ACCD, and AVAV.

In a report released yesterday, Terence Flynn from Morgan Stanley maintained a Buy rating on Crispr Therapeutics AG (CRSP – Research Report), ...

SG Americas Securities LLC decreased its holdings in CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 17.9% during the 4th quarter, according to the company in its most recent disclosure with the ...

Learn more about whether Catalyst Pharmaceuticals, Inc. or CRISPR Therapeutics AG is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

A live webcast of the fireside chat will be available on the "Events & Presentations" page in the Investors section of the Company's website at https://crisprtx.gcs-web.com/events. A replay of the ...

CRISPR Therapeutics AG (CRSP) closed at $41.21 in the latest trading session, marking a -1.44% move from the prior day. The stock trailed the S&P 500, which registered a daily loss of 0.47%.

CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Boston, Massachusetts and San Francisco ...